Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Lakeshore said

lakeshore555 Monday, 04/14/14 08:20:52 AM
Re: dcspka post# 20745
Post # of 20752
I am an objective investor. I am not, however, an investor who invests in rumors. I like evidence, especially SEC filings.


Wolf Says

Here is your SEC Filing..The 6000USD was used for the Patent..He indeed made a payment. Unfortunately, a creeping takeover group does not broadcast their Full intentions..Since Radient is a pinkie sheet, they are not required to file with the SEC, only what they want you to see and to protect them as well..So the filing was posted..Whatever happens after the deadline.You have two choices..Either William Paid the remaining 274 thousand dollars after the 90 Day deadline and grace period or he didn't. We are betting he did? Proof? Trademark activity and patent activity in February 2013..All these facts have been posted..And they were agreed to within the scope of the agreement you understand..Wolf ahoooooooooo



Section 1 - Registrant’s Business and Operations

Item 1.01 - Entry into Material Definitive Agreements



On July 17, 2012, we filed a Form 8-K to disclose a license agreement we entered into with Global Cancer Diagnostics, Inc. ("GCDx") in order to commercialize certain of our intellectual property in the form of a Lung Cancer test (the “Agreement”). Section 3.1 of the Agreement was amended on August 23, 2012 (the “Amendment”), with the remainder of the Agreement unchanged. Pursuant to the Amendment, GCDx will pay us an upfront license fee of $250,000 immediately upon receipt of funds from the first closing of its current financing for approximately $2,000,000, which was anticipated to close no later than September 15, 2012. On September 14, 2012, we agreed to further amend Section 3.1 of the Agreement and replace it with the following:


“GCDx will pay a License Fee of Two Hundred and Eighty Thousand Dollars ($280,000) to RXPC immediately upon receipt of it funding in the amount of Two Million dollars, or on or before October 1, 2012. As of the date of this amendment, GCDx has paid a total of US$6,000 towards this licensing fee.”

As of October 1, 2012, GCDx has not made the required upfront payment of $280,000. Therefore the proposed GCDx licensing agreement was cancelled. We will consider re-engaging GCDx in a new licensing agreement at such time as GCDx is able to make the required up-front payment.


http://www.sec.gov/Archives/edgar/data/838879/000114420412054967/v325211_8ka.htm

Columbo Says "Just One More Thing"


Lake isn't it funny that some will say William's agreement was null and void, but they claim Uni 's agreement is fina;ized? Why is one considered one way and the other the other way? Both have not filed since their original filings. What do you say?

Section 1 - Registrant’s Business and Operations

Item 1.01 - Entry into Material Definitive Agreements

We filed a Current Report on Form 8-K on June 11, 2013 to disclose our entry into a 5-year license agreement between AMDL Diagnostics, Inc. (“ADI”), a division within our company, and Uni Pharma Co., Ltd. a Taipei Taiwan limited liability company (“UNI”) that provides UNI with a 5-year exclusive license (subject to automatic renewal for an additional 5 years) to RXPC’s Onko-Sure® (formerly called DR-70 cancer blood test kits (the “Tests”), procedures, analyses, data, know how, manufacturing, manufacturing processes, components, trademarks and intellectual property.

The initial 8-K and the agreement attached as Exhibit 10.1 to the initial 8-K inaccurately disclosed that UNI only has exclusive license rights in Taiwan; however, the final agreement provides UNI with exclusive rights to the license in all of the following territories: Taiwan ROC, China PRC, Hong Kong, Malaysia, Singapore, Indonesia, Thailand, Japan, India, Turkey Australia and New Zealand. We are filing this amendment to disclose same and to file the final version of the agreement as an exhibit.


http://www.sec.gov/Archives/edgar/data/838879/000121390013003193/f8k061113a1_radient.htm